Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Donaperminogene seltoplasmid - Helixmith

Drug Profile

Donaperminogene seltoplasmid - Helixmith

Alternative Names: Donaperminogene seltoplasmid; Engensis; Hepatocyte growth factor gene therapy-Helixmith; HGF plasmid; Modified hepatocyte growth factor gene therapy-Helixmith; NL003; pCK-HGF-X7; VM-202; VM202-ALS; VM202-CAD; VM202-DPN; VM202-PAD; VM202-Stent; VM202RY

Latest Information Update: 01 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ViroMed Co Ltd
  • Developer Beijing Northland Biotech; Helixmith; Reyon Pharmaceutical
  • Class Anti-ischaemics; Foot disorder therapies; Gene therapies; Neuroprotectants; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inducing agents; Gene transference; Hepatocyte growth factor expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity No

Highest Development Phases

  • Phase III Chronic limb-threatening ischemia; Diabetic foot ulcer; Diabetic neuropathies
  • Phase II Amyotrophic lateral sclerosis; Coronary artery disease; Myocardial infarction
  • Phase I/II Charcot-Marie-Tooth disease
  • No development reported Ischaemic heart disorders; Myocardial ischaemia

Most Recent Events

  • 05 Sep 2023 Northwestern University and ViroMed completes the phase II HI-PAD trial for Peripheral arterial disorders in USA (NCT03363165)
  • 17 Jul 2023 Phase-II clinical trials in Coronary artery disease in South Korea (IM), prior to July 2023 (Reyon Pharmaceuticals pipeline, July 2023)
  • 09 Jan 2023 Helixmith terminates a phase III trial in Diabetic foot ulcer in USA (IM) due to low enrollment (NCT02563522)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top